Recordati Industria Chimica E Farmaceutica Q2 2026 Earnings Report

Recordati Industria Chimica E Farmaceutica EPS Results

• Actual EPS: $0.91
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Recordati Industria Chimica E Farmaceutica Revenue Results

• Actual Revenue: $810.70 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Recordati Industria Chimica E Farmaceutica Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is an Italian pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its activities are centered on specialty-care and rare-disease treatments, with products addressing areas such as endocrinology, oncology, urology, cardiology, gastroenterology and other specialized medical needs.

The company markets both proprietary and licensed medicines, serving patients through prescription products and therapies for uncommon or underserved conditions. Its rare-disease portfolio includes treatments for certain endocrine disorders and oncology-related conditions, while its broader specialty-care operations include established medicines distributed through its commercial organization and selected partnerships.

Founded in Milan in 1926, Recordati has expanded from an Italian pharmaceutical business into an international company. It serves markets across Europe and in other regions, including selected countries in the Middle East, North Africa, Turkey and the United States. The company operates through research, manufacturing and commercial activities supported by a network of subsidiaries and partners.